Novartis, Pfizer join forces on potentially lucrative fatty liver disease
Novartis AG and Pfizer Inc are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Diabetes | Eating Disorders & Weight Management | Endocrinology | Epidemics | Epidemiology | Fatty Liver Disease (FLD) | Health | Liver | Liver Disease | Obesity | Pfizer | Urology & Nephrology